Who is Foundayo suitable for?

Quick answer

UK authorisation covers adults with insufficiently controlled type 2 diabetes and, separately, adult weight management at BMI 30 or above or BMI 27 to below 30 with a weight-related condition, alongside lifestyle measures. Eligibility does not establish personal suitability; a prescriber must consider the individual and current product information.

In the UK, Foundayo is authorised for adults with type 2 diabetes whose blood sugar is not adequately controlled, and for adult weight management alongside reduced-calorie eating and increased activity: BMI 30 or above, or BMI 27 to below 30 with at least one weight-related condition. A licence sets eligible groups; a clinician must still assess whether it is appropriate.

What do the BMI criteria mean?

BMI, or body mass index, is a measure calculated from height and weight. A BMI threshold helps define the licensed weight-management population, but it does not capture every aspect of health. The authorisation includes weight loss and weight maintenance in adults with obesity (BMI 30 or above), or overweight (BMI from 27 to below 30) when at least one weight-related comorbidity is present. A comorbidity is another health condition associated with excess weight. Treatment is used alongside a reduced-calorie diet and increased physical activity.

Is the diabetes indication different?

There is a separate authorised use: improving blood-sugar control in adults with insufficiently controlled type 2 diabetes. The diabetes indication is not the same as the weight-management criteria. Do not assume that meeting a BMI threshold alone establishes suitability, or that having type 2 diabetes means the medicine is appropriate for you. A prescriber reviews your clinical circumstances, other medicines and treatment goals.

What does UK authorisation establish?

Foundayo contains orforglipron, an oral GLP-1 receptor agonist. The MHRA authorised it in the UK on 10 August 2026 as a prescription-only medicine. An authorisation is not a personal recommendation, a promise of benefit, or evidence that it is right for every adult in the authorised group. People may need a different approach because of medical history, tolerability, interactions or preference.

What should your clinician review?

Tell your healthcare professional about all medicines and supplements you take, previous treatment with GLP-1 medicines, and relevant health conditions. GLP-1 medicines can affect digestion; the clinician can discuss expected effects and when to seek help. Do not use online eligibility descriptions as a substitute for assessment or alter existing diabetes treatment on your own.

Pregnancy and treatment planning

Pregnancy requires particular care. Tell the prescriber if you are pregnant, planning to become pregnant or breastfeeding, and seek advice before starting or continuing treatment. Weight-management treatment is not appropriate as a goal during pregnancy; diabetes care in pregnancy needs individual specialist guidance. Confirm the advice in the current MHRA patient leaflet and with your clinical team.

Questions to ask

If you are unsure which indication applies, ask the clinician to explain the intended treatment goal and how progress and safety will be reviewed. The licensed group describes who may be considered—not who must take it.

Eligibility is not a recommendation

Eligibility and prescribing are not identical concepts. The MHRA authorisation defines circumstances in which a medicine can be used; a prescriber still considers the person’s full history, potential benefits and risks, and whether the medicine aligns with the treatment plan. Bring questions about previous medicines, digestion-related symptoms, allergies and planned procedures to the consultation. This article cannot determine suitability remotely. The clinic should explain how follow-up works and what to do if treatment is not tolerated, and should use the current product information rather than an old leaflet or social-media summary. Bring any uncertainties to a qualified clinician or pharmacist, who can check the current UK product information and your individual circumstances. Online summaries are useful starting points, not a substitute for that review.